Physicochemical Properties
| CAS # | 2882904-64-3 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Target: Filamenting temperature-sensitive mutant Z (FtsZ)[1] |
| ln Vitro | Minimum bactericidal concentration (MBC) is the same as minimum inhibition concentration (MIC). Compound 30, FtsZ-IN-4, demonstrates strong antibacterial activity against S. aureus and B. subtilis, with MICs of 0.008–0.25 μg/mL, respectively[1]. The bactericidal effects of FtsZ-IN-4 (0.064 μg/mL or 0.5 μg/mL; 0-24 h) are demonstrated within 3 hours, and the MBC/MIC ratios are ≤4, meeting CLSI standards[1]. FtsZ-IN-4 exhibits minimal cytotoxicity against Vero cells (>20 μg/mL; 72 h) [1]. Bacteria are lengthened by FtsZ-IN-4 (0.016 μg/mL; 3 h), which also induces aberrant bacterial cell division and ultimately results in bacterial cell death[1]. SaFtsZ polymerization is induced by FtsZ-IN-4 (10 μg/mL; 0–15 min), and SaFtsZ GTPase activity is dose-dependently inhibited by FtsZ-IN-4 (0–35 μg/mL; 30 min)[1]. |
| ln Vivo | FtsZ-IN-4 (compound 30) (5 mg/kg; po) in mice shows a moderate exposure (AUC(0-t) = 544.2 h*ng/mL) and 61.2% oral bioavailability (F)[1]. Mice treated with FtsZ-IN-4 (25 mg/kg; iv) exhibit good in vivo effectiveness. The pharmacokinetic profiles of FtsZ-IN-4 in mice were as follows: Route Dose (mg/kg) T1/2 (h) Tmax (h) Cmax (ng/mL) AUC(0-t) (h·ng/mL) AUC(0-∞) (h·ng/mL) Vss (ng/mL) CL (mL/h/kg) F (%) iv 1 0.28 0.083 480.5 177.8 178.7 1545.5 5682.8 / 5 2.26 0.5 429.3 544.2 559.3 / / 61.2 |
| Cell Assay |
Cell Cytotoxicity Assay[1] Cell Types: Vero cells (African green monkey kidney cells) Tested Concentrations: >20 μg/mL Incubation Duration: 72 hrs (hours) Experimental Results: demonstrated the 50% cytotoxic concentration (CC50) >20 μg/ mL, much more than the inhibition of B. subtilis ATCC9372 (MIC =0.016 μg/mL). Cell Proliferation Assay[1] Cell Types: S. aureus ATCC25923 and Bacillus ATCC9372 Tested Concentrations: 1×, 2×, 4×, 8× MIC; MIC =0.125 μg/mL (S. aureus); 0.016 μg/mL (Bacillus) Incubation Duration: 3, 6, 12, 24 hrs (hours) Experimental Results: diminished B. subtilis ATCC9372 and S. aureus ATCC25923 cells below the lowest detectable limit (103 CFU/mL) in 3 h. |
| Animal Protocol |
Animal/Disease Models: Male ICR mice (infected with S. aureus ATCC25923)[1] Doses: 25 mg/ kg Route of Administration: intraperitoneal (ip) injection; 0.5 mL Experimental Results: Dramatically decreased the bacterial burden and demonstrated comparable in vivo efficacy with vancomycin. |
| References | [1]. Deng J, et al. Design, synthesis and biological evaluation of biphenyl-benzamides as potent FtsZ inhibitors. Eur J Med Chem. 2022 Sep 5. 239:114553. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |